We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 04, 2021

Ipilimumab/Nivolumab Consolidation After Chemoradiation in Limited Disease Small-Cell Lung Cancer

Annals of Oncology


Additional Info

Annals of Oncology
Consolidation Nivolumab and Ipilimumab Versus Observation in Limited-Disease Small Cell Lung Cancer After Chemo-Radiotherapy - Results From the Randomised Phase II ETOP/IFCT 4-12 STIMULI Trial
Ann. Oncol 2021 Sep 22;[EPub Ahead of Print], S Peters, JL Pujol, U Dafni, M Dómine, S Popat, M Reck, J Andrade, A Becker, D Moro-Sibilot, A Curioni-Fontecedro, O Molinier, K Nackaerts, AI Mollá, R Gervais, GL Vivanco, J Madelaine, J Mazieres, M Faehling, F Griesinger, M Majem, JLG Larriba, MP Pulla, K Vervita, H Roschitzki-Voser, B Ruepp, P Mitchell, RA Stahel, C Le Pechoux, D De Ruysscher

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading